Senti Biosciences CEO Timothy Lu Discusses Company's Gene Circuit Platform and Programs

Senti Biosciences announced that Timothy Lu, Co-Founder and CEO, participated in a virtual investor conference, discussing his dedication to the company and its programs in development. The on-demand video webcast is now available on the company's website and virtualinvestorco.com. Senti Bio is a biotechnology company developing next-generation cell and gene therapies for incurable diseases using its proprietary Gene Circuit platform.

Senti Biosciences (NASDAQ: SNTI), a clinical-stage biotechnology company, recently participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. The company's Co-Founder and CEO, Dr. Timothy Lu, presented at the event, sharing insights into his journey, dedication to the company, and passion for their development programs [1].

Dr. Lu delved into his dedication to Senti Bio, discussing how he got to where he is today and providing insight into why he is so passionate about the company’s programs in development. The presentation, which focuses on Senti's proprietary Gene Circuit platform for next-generation cell and gene therapies, is now available for viewing on virtualinvestorco.com and the company's investor relations website [1].

Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. The company leverages its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target tissues, and be controllable even after administration. The company’s wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships [1].

Additionally, Senti Bio recently appointed Bryan Baum to its Board of Directors. Mr. Baum is a serial entrepreneur and investor, and the Co-Founder and Managing Partner of K5 Global. His portfolio includes category-defining companies such as SpaceX, xAI, Anduril, Canva, Databricks, Grafana, and OpenAI. He has also founded and successfully exited multiple ventures, including Parrot, Blue Vision Labs, Operam, and Represent.com. Mr. Baum has been an angel investor for over a decade and has personally made over 200 investments in companies such as Uber, Airbnb, Slack, Flexport, Carta, PillPack, and Sweetgreen. His appointment to the board reflects Senti Bio's commitment to advancing its programs and optimizing value for stakeholders [2].

The on-demand video webcast is now available on virtualinvestorco.com as well as the Events page under the Investors section of the Company’s website (sentibio.com) [1].

References:
[1] https://www.stocktitan.net/news/SNTI/senti-biosciences-participates-in-the-virtual-investor-what-s-your-ugzet2ktueyo.html
[2] https://investors.sentibio.com/news-releases/news-release-details/senti-bio-appoints-entrepreneurial-leader-and-investor-bryan